agen2373
mAbexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 4, 2019 (NCT04121676)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFRSF9 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07193862 | Early Phase 1 (Phase 1) | Oct 15, 2025 | Northwell Health |
| NCT06782932 | Phase 1/Phase 2 (Phase 2) | May 27, 2025 | Agenus Inc., Johns Hopkins University, Lustgarten Foundation, Oncovir, Inc. |
| NCT04121676 | Phase 1 | Oct 4, 2019 | Agenus Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Agenus Inc. | For profit | 2 | 1 | 2 | 2019 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Lustgarten Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Northwell Health | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1